A comparison of atenolol and nebivolol in isolated systolic hypertension

被引:162
作者
Dhakam, Zahid [1 ]
Yasmin [1 ]
McEniery, Carmel M. [1 ]
Burton, Tim [1 ]
Brown, Morris J. [1 ]
Wilkinson, Ian B. [1 ]
机构
[1] Univ Cambridge, Addenbrookes Hosp, Clin Pharmacol Unit, Cambridge CB2 2QQ, England
关键词
augmentation index; beta blockers; hypertension; pulse wave velocity;
D O I
10.1097/HJH.0b013e3282f283c9
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Objectives Some beta-blockers are less effective in reducing central blood pressure than other antihypertensive drugs, which may explain the higher rate of events in subjects randomized to atenolol in recent trials. We hypothesized that nebivolol, a mixed beta-blocker/ nitro-vasodilator, would be more effective than atenolol in reducing central blood pressure and augmentation index ( AIx). The aim of the present study was to test this in a double-blind, randomized, cross-over study, in a cohort of subjects with isolated systolic hypertension. Methods Following a 2-week placebo run-in, 16 never-treated hypertensive subjects received atenolol ( 50 mg), nebivolol ( 5 mg) and placebo, each for 5 weeks, in a random order. Seated brachial blood pressure and heart rate were measured. Aortic blood pressure, AIx and pulse wave velocity ( PWV) were assessed non-invasively. Results The placebo-corrected fall in brachial pressure was similar between nebivolol and atenolol, as was the reduction in PWV ( mean change +/- SEM: -1.0 +/- 0.3 and -1.2 +/- 0.2 m/s; P=0.2). However, there was less reduction in heart rate (-19 +/- 2 versus -23 +/- 2 beats/ min; P< 0.01) and increase in AIx (+6 +/- 1 versus +10 +/- 1%; P=0.04), following nebivolol. Aortic pulse pressure was significantly lower ( 50 +/- 2 versus 54 +/- 2mmHg; P=0.02) after nebivolol. N-terminal pro-B-type natriuretic peptide ( proBNP) rose on both drugs (100 +/- 33 versus 75 +/- 80 pg/ ml; P< 0.01 for both, NS for comparison). Conclusions Nebivolol and atenolol have similar effects on brachial blood pressure and aortic stiffness. However, nebivolol reduces aortic pulse pressure more than atenolol, which may be related to a less pronounced rise in AIx and bradycardia. Whether this will translate into differences in clinical outcome requires further investigation.
引用
收藏
页码:351 / 356
页数:6
相关论文
共 41 条
[1]   Central blood pressure measurements and antihypertensive therapy a consensus document [J].
Agabiti-Rosei, Enrico ;
Mancia, Giuseppe ;
O'Rourke, Michael F. ;
Roman, Mary J. ;
Safar, Michel E. ;
Smulyan, Harold ;
Wang, Ji-Guang ;
Wilkinson, Ian B. ;
Williams, Bryan ;
Vlachopoulos, Charalambos .
HYPERTENSION, 2007, 50 (01) :154-160
[2]   SYMPATHETIC ACTIVATION DECREASES MEDIUM-SIZED ARTERIAL COMPLIANCE IN HUMANS [J].
BOUTOUYRIE, P ;
LACOLLEY, P ;
GIRERD, X ;
BECK, L ;
SAFAR, M ;
LAURENT, S .
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 1994, 267 (04) :H1368-H1376
[3]   Local pulse pressure and regression of arterial wall hypertrophy during long-term antihypertensive treatment [J].
Boutouyrie, P ;
Bussy, C ;
Hayoz, D ;
Hengstler, J ;
Dartois, N ;
Laloux, B ;
Brunner, H ;
Laurent, S .
CIRCULATION, 2000, 101 (22) :2601-2606
[4]   Arterial pressure lowering effect of chronic atenolol therapy in hypertension and vasoconstrictor sympathetic drive [J].
Burns, J ;
Mary, DASG ;
Mackintosh, AF ;
Ball, SG ;
Greenwood, JP .
HYPERTENSION, 2004, 44 (04) :454-458
[5]   Evaluation of the sympathetic nervous system using heart rate variability and plasma hormones in hypertensive patients treated with cilazapril and atenolol [J].
Campelo, M ;
Polonia, J ;
Serrao, P ;
CerqueiraGomes, M .
CARDIOLOGY, 1996, 87 (05) :402-408
[6]   Atenolol in hypertension: is it a wise choice? [J].
Carlberg, B ;
Samuelsson, O ;
Lindholm, LJ .
LANCET, 2004, 364 (9446) :1684-1689
[7]   DIFFERENT EFFECTS OF FOSINOPRIL AND ATENOLOL ON WAVE REFLECTIONS IN HYPERTENSIVE PATIENTS [J].
CHEN, CH ;
TING, CT ;
LIN, SJ ;
HSU, TL ;
YIN, FCP ;
SIU, CO ;
CHOU, P ;
WANG, SP ;
CHANG, MS .
HYPERTENSION, 1995, 25 (05) :1034-1041
[8]   Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):: a randomised trial against atenolol [J].
Dahlöf, B ;
Devereux, RB ;
Kjeldsen, SE ;
Julius, S ;
Beevers, G ;
de Faire, U ;
Fyhrquist, F ;
Ibsen, H ;
Kristiansson, K ;
Lederballe-Pedersen, O ;
Lindholm, LH ;
Nieminen, MS ;
Omvik, P ;
Oparil, S ;
Wedel, H .
LANCET, 2002, 359 (9311) :995-1003
[9]   The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes [J].
de Lemos, JA ;
Morrow, DA ;
Bentley, JH ;
Omland, T ;
Sabatine, MS ;
McCabe, CH ;
Hall, C ;
Cannon, CP ;
Braunwald, E .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (14) :1014-1021
[10]  
Deary AJ, 2002, CLIN SCI, V103, P493